Autopsy report · NCT00169104

Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

“Closed due to achievement of primary study endpoint”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 2 months after it had already started.
• Ran for about 6 years 8 months before it stopped.
• 23 participants enrolled.
• Results were posted on the registry 9 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Dartmouth-Hitchcock Medical Center

Sponsor type

University, hospital or other

Conditions

Metastatic Breast Cancer

Interventions

G-CSF; trastuzumab; vinorelbine; G-CSF; saline placebo

Participants

23

Trials that died the same way

• High Dose Rate Brachyablation of Primary Liver Lesions
  “Study was closed due to poor accrual” (72% match in meaning)
• A Supportive Care Intervention for Older Caregivers of Older Adults with Advanced Cancer
  “Study has been closed to accrual earlier than anticipated and will not resume.” (68% match in meaning)
• Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
  “Study was closed to low accrual.” (68% match in meaning)
• Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma
  “Study closed due to feasability” (67% match in meaning)
• COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
  “The study was closed due to continued enrollment hurdles.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.